Megestrol

17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Also Known As:

Networked: 80 relevant articles (10 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jahn, Holger: 2 articles (01/2006 - 12/2003)
2.	Raedler, Thomas J: 2 articles (01/2006 - 12/2003)
3.	Goedeken, Birgit: 2 articles (01/2006 - 12/2003)
4.	Wiedemann, Klaus: 2 articles (01/2006 - 12/2003)
5.	Kellner, Michael: 2 articles (01/2006 - 12/2003)
6.	Gescher, Dorothee M: 2 articles (01/2006 - 12/2003)
7.	Allen, Carrie: 1 article (07/2015)
8.	Zarowitz, Barbara J: 1 article (07/2015)
9.	O'Shea, Terrence: 1 article (07/2015)
10.	Strauss, Marcie E: 1 article (07/2015)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 11/01/2003 - "An economic model was developed based on data from phase III megestrol-controlled clinical trials of antiaromatase agents (AA) and estimates of resource utilization from both Statistic Canada's Population Health Model for breast cancer and expert opinion. " 04/02/1984 - " Megestrol, a gestagen, was found to cause breast tumors in beagles and was withdrawn from the market. " 10/01/1999 - "It has been shown to be effective third-line therapy after tamoxifen and megestrol in postmenopausal patients with metastatic breast cancer. " 10/01/2000 - "Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol." 06/01/1991 - "The next generation of adjuvant trials in breast cancer needs to explore the potential of an alternating tamoxifen/megestrol regimen."
2.	Disease Progression 10/01/1999 - "Results from a phase III trial indicate that exemestane achieves a similar objective response rate to megestrol as a second-line therapy; however, exemestane achieved a significantly longer duration of overall success, time to disease progression and survival time. " 06/01/2000 - "However, the duration of overall success and times to disease progression and treatment failure were significantly prolonged with exemestane compared with megestrol. " 06/01/2000 - "Exemestane is effective in postmenopausal patients with tamoxifen-refractory advanced breast cancer, prolonging time to disease progression and treatment failure and improving survival compared with megestrol treatment. " 01/01/2006 - "In women with hormone-responsive advanced breast cancer, letrozole is superior to tamoxifen in prolonging the time to disease progression and time to treatment failure in a first-line setting, and is at least as effective as anastrozole and more effective than megestrol for some endpoints (in one of two trials) in a second-line setting. "
3.	Hepatocellular Carcinoma (Hepatoma) 04/06/2001 - "Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (P = 0.0090). " 11/16/2001 - "Megestrol treatment in patients with hepatocellular carcinoma." 04/06/2001 - "Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors." 02/01/2010 - "Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era." 04/01/2005 - "Nine cirrhotic patients with advanced hepatocellular carcinoma received oral megestrol (160 mg/day) and thalidomide (from 50 mg/day to the maximal tolerated dose). "
4.	Hot Flashes 12/01/2004 - "Megestrol has also been used as an appetite stimulant for patients with human immunodeficiency virus and malignancy who experience cachexia and wasting; also, megestrol can be beneficial in relieving hot flashes in women and men. " 06/01/2002 - "depot MPA injections provides significant and long-lasting relief from postmenopausal hot flashes in patients with a history of breast cancer, offering an alternative to estrogen replacement therapy or prolonged administration of oral megestrol." 06/01/2002 - "Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study."
5.	Neoplasms (Cancer) 04/30/1995 - "The results of the study indicate comparable efficacy (using tumor clearance as an end point) of DES and Megestrol. " 03/01/1989 - "The results of the study indicate comparable efficacy (using tumor clearance as an end-point) of DES and Megestrol. " 02/01/2010 - "At 3 months, tumor burden was more frequently stable with megestrol, while performance status was significantly better in patients treated with Synchro-Levels. " 02/01/2010 - "Most patients had multifocal disease (75% in megestrol and 59% in Synchro-Levels) and there was a significant difference in tumor burden, with more advanced disease in the megestrol arm (P = 0.0002). " 11/01/2005 - "A 21- x 18-mm residual area of neoplasm in the lung completely resolved 3 months after treatment with megestrol. "

Related Drugs and Biologics

1.	Tamoxifen
2.	anastrozole (Arimidex)
3.	Hormones
4.	letrozole (Femara)
5.	exemestane (Aromasin)
6.	Gonadotropin-Releasing Hormone (GnRH)
7.	nedaplatin
8.	Hydrocortisone (Cortisol)
9.	Megestrol Acetate (Borea)
10.	Medroxyprogesterone

Related Therapies and Procedures

1.	Combination Drug Therapy (Combination Chemotherapy)
2.	Estrogen Replacement Therapy
3.	Injections
4.	Radiotherapy
5.	Oral Administration